{ "@graph": [    { "@id": "http://linked.opendata.cz/resource/ATC/L",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" , "@language" : "en" } ,        { "@value" : "Cytostatika a imunomodula\u010Dn\u00ED l\u00E9\u010Diva" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "L" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/L03",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Immunomodulators/-stimulants " , "@language" : "en" } ,        { "@value" : "Imunostimulancia" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "L03" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/L03A",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Imunostimulancia" , "@language" : "cs" } ,        { "@value" : "Immunostimulants " , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "L03A" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/L03AA",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Faktory stimuluj\u00EDc\u00ED kolonie hematopoetick\u00FDch bun\u011Bk (CSF)" , "@language" : "cs" } ,        { "@value" : "Colony stimulating factors" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "L03AA" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/L03AA02",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://www.w3.org/2004/02/skos/core#broaderTransitive" : [ "http://linked.opendata.cz/resource/ATC/L03A" ,        "http://linked.opendata.cz/resource/ATC/L03" ,        "http://linked.opendata.cz/resource/ATC/L" ,        "http://linked.opendata.cz/resource/ATC/L03AA" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Filgrastim" , "@language" : "cs" } ,        { "@value" : "Filgrastim" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "L03AA02" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ndfrt/disease/N0000000999",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/DiseaseOrFinding" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Drug hypersensitivity" , "@language" : "en" } ,        { "@value" : "L\u00E9kov\u00E1 alergie" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0028831",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/Ingredient" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Filgrastim" , "@language" : "en" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPregnancyCategory" : [ "http://linked.opendata.cz/resource/fda-spl/pregnancy-category/C" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/contraindicatedWith" : [ "http://linked.opendata.cz/resource/ndfrt/disease/N0000000999" ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product/NEUPOGEN-48-MU-0-5-ML",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProduct" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasActiveIngredient" : [ "http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0028831" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "NEUPOGEN 48 MU/0,5 ML" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/L03AA02" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPregnancyCategory" : [ "http://linked.opendata.cz/resource/fda-spl/pregnancy-category/C" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasMedicinalProductPackaging" : [ "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0078906" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0078905" ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0078906",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "NEUPOGEN 48 MU/0,5 ML" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/L03AA02" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "VARIA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC135710_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "5X0.5ML" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Injekce" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "0.96MG/ML" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "NEUPOGEN je ur\u010Den ke zkr\u00E1cen\u00ED doby trv\u00E1n\u00ED neutropenie a sn\u00ED\u017Een\u00ED v\u00FDskytu febriln\u00ED neutropenie u pacient\u016F l\u00E9\u010Den\u00FDch zavedenou cytotoxickou chemoterapi\u00ED pro malign\u00ED n\u00E1dorov\u00E9 onemocn\u011Bn\u00ED (s v\u00FDjimkou chronick\u00E9 myeloidn\u00ED leukemie a myelodysplastick\u00FDch syndrom\u016F) a ke zkr\u00E1cen\u00ED obdob\u00ED neutropenie u pacient\u016F l\u00E9\u010Den\u00FDch myeloablativn\u00ED terapi\u00ED n\u00E1sledovanou transplantac\u00ED kostn\u00ED d\u0159en\u011B, kte\u0159\u00ED jsou pova\u017Eov\u00E1ni za zv\u00FD\u0161en\u011B ohro\u017Een\u00E9 prolongovanou t\u011B\u017Ekou neutropeni\u00ED. \nBezpe\u010Dnost a \u00FA\u010Dinnost NEUPOGENU jsou obdobn\u00E9 jak u dosp\u011Bl\u00FDch, tak i u d\u011Bt\u00ED, l\u00E9\u010Den\u00FDch cytotoxickou chemoterapi\u00ED. \nNEUPOGEN je ur\u010Den k\u00A0mobilizaci perifern\u00EDch kmenov\u00FDch (progenitorov\u00FDch) bun\u011Bk ( peripheral blood progenitor cells -PBPC ).\nDlouhodob\u00E9 pod\u00E1v\u00E1n\u00ED NEUPOGENU ke zv\u00FD\u0161en\u00ED po\u010Dtu neutrofil\u016F a sn\u00ED\u017Een\u00ED \u010Detnosti v\u00FDskytu a d\u00E9lky trv\u00E1n\u00ED infek\u010Dn\u00EDch komplikac\u00ED je indikov\u00E1no u pacient\u016F, d\u011Bt\u00ED nebo dosp\u011Bl\u00FDch, s\u00A0t\u011B\u017Ekou vrozenou (kongenit\u00E1ln\u00ED), cyklickou nebo idiopatickou neutropeni\u00ED, kte\u0159\u00ED maj\u00ED ANC (absolutn\u00ED po\u010Det neutrofil\u016F) ( 0,5 x 109/l a t\u011B\u017Ek\u00E9 nebo opakovan\u00E9 infekce v\u00A0anamn\u00E9ze.\nNEUPOGEN je ur\u010Den k l\u00E9\u010Db\u011B p\u0159etrv\u00E1vaj\u00EDc\u00ED neutropenie (ANC ni\u017E\u0161\u00ED nebo roven 1,0 x109/l) u pacient\u016F s pokro\u010Dilou formou HIV infekce, aby se omezilo riziko bakteri\u00E1ln\u00EDch infekc\u00ED tam, kde jsou dal\u0161\u00ED mo\u017Enosti l\u00E9\u010Dby neutropenie nevhodn\u00E9. \n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasMaximalPrice" : [ { "@value" : 15262.8203125 , "@type" : "http://www.w3.org/2001/XMLSchema#float" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasReimbursementAmount" : [ { "@value" : 15821.490234375 , "@type" : "http://www.w3.org/2001/XMLSchema#float" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INJ SOL 5X0.5ML" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0078905",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "NEUPOGEN 48 MU/0,5 ML" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/L03AA02" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "VARIA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC135710_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "1X0.5ML" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Injekce" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "0.96MG/ML" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "NEUPOGEN je ur\u010Den ke zkr\u00E1cen\u00ED doby trv\u00E1n\u00ED neutropenie a sn\u00ED\u017Een\u00ED v\u00FDskytu febriln\u00ED neutropenie u pacient\u016F l\u00E9\u010Den\u00FDch zavedenou cytotoxickou chemoterapi\u00ED pro malign\u00ED n\u00E1dorov\u00E9 onemocn\u011Bn\u00ED (s v\u00FDjimkou chronick\u00E9 myeloidn\u00ED leukemie a myelodysplastick\u00FDch syndrom\u016F) a ke zkr\u00E1cen\u00ED obdob\u00ED neutropenie u pacient\u016F l\u00E9\u010Den\u00FDch myeloablativn\u00ED terapi\u00ED n\u00E1sledovanou transplantac\u00ED kostn\u00ED d\u0159en\u011B, kte\u0159\u00ED jsou pova\u017Eov\u00E1ni za zv\u00FD\u0161en\u011B ohro\u017Een\u00E9 prolongovanou t\u011B\u017Ekou neutropeni\u00ED. \nBezpe\u010Dnost a \u00FA\u010Dinnost NEUPOGENU jsou obdobn\u00E9 jak u dosp\u011Bl\u00FDch, tak i u d\u011Bt\u00ED, l\u00E9\u010Den\u00FDch cytotoxickou chemoterapi\u00ED. \nNEUPOGEN je ur\u010Den k\u00A0mobilizaci perifern\u00EDch kmenov\u00FDch (progenitorov\u00FDch) bun\u011Bk ( peripheral blood progenitor cells -PBPC ).\nDlouhodob\u00E9 pod\u00E1v\u00E1n\u00ED NEUPOGENU ke zv\u00FD\u0161en\u00ED po\u010Dtu neutrofil\u016F a sn\u00ED\u017Een\u00ED \u010Detnosti v\u00FDskytu a d\u00E9lky trv\u00E1n\u00ED infek\u010Dn\u00EDch komplikac\u00ED je indikov\u00E1no u pacient\u016F, d\u011Bt\u00ED nebo dosp\u011Bl\u00FDch, s\u00A0t\u011B\u017Ekou vrozenou (kongenit\u00E1ln\u00ED), cyklickou nebo idiopatickou neutropeni\u00ED, kte\u0159\u00ED maj\u00ED ANC (absolutn\u00ED po\u010Det neutrofil\u016F) ( 0,5 x 109/l a t\u011B\u017Ek\u00E9 nebo opakovan\u00E9 infekce v\u00A0anamn\u00E9ze.\nNEUPOGEN je ur\u010Den k l\u00E9\u010Db\u011B p\u0159etrv\u00E1vaj\u00EDc\u00ED neutropenie (ANC ni\u017E\u0161\u00ED nebo roven 1,0 x109/l) u pacient\u016F s pokro\u010Dilou formou HIV infekce, aby se omezilo riziko bakteri\u00E1ln\u00EDch infekc\u00ED tam, kde jsou dal\u0161\u00ED mo\u017Enosti l\u00E9\u010Dby neutropenie nevhodn\u00E9. \n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INJ SOL 1X0.5ML" , "@language" : "cs" } ] }] }